Online inquiry

IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15734MR)

This product GTTS-WQ15734MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SEMA4D gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001142287.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10507
UniProt ID Q92854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15734MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5304MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ9402MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ6624MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ14661MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ9590MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ548MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ2773MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ6139MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-675
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW